Affymax says to continue studying anemia drug
Aug 7 (Reuters) - Affymax Inc (AFFY.O) said an independent data monitoring committee has determined that the company can continue studying its anemia drug in late-stage trials.
Hematide is being evaluated to treat anemia in chronic renal failure patients on dialysis and not on dialysis.
Shares of Affymax closed at $20.40 Thursday on Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Anil D'Silva)
© Thomson Reuters 2009 All rights reserved
Citadel enters the fray
Kenneth Griffin's powerful hedge fund has waded into the case of Goldman Sachs' purloined computer code, suing three of its former employees for setting up Teza Technologies. Full Article | Full Coverage
